Please login to the form below

Not currently logged in
Email:
Password:

Acorda

This page shows the latest Acorda news and features for those working in and with pharma, biotech and healthcare.

Biogen pays $590m for Pfizer cognition drug

Biogen pays $590m for Pfizer cognition drug

The biotech company has also been linked to a possible takeover offer for Acorda Therapeutics and its Parkinson’s diseases candidates Inbrija (inhaled levodopa) and SYN-201.

Latest news

  • Acorda acquires Biotie to expand in Parkinson's disease Acorda acquires Biotie to expand in Parkinson's disease

    Acorda acquires Biotie to expand in Parkinson's disease. Strikes $363m deal for Finnish firm. ... Acorda Therapeutics has agreed to buy Finland's Biotie Therapies in a $363m deal that swells its pipeline of Parkinson's disease (PD) drug candidates.

  • Pharma deals for February 2012 Pharma deals for February 2012

    For example, the acquisition of the privately-owned Neuronex, with its diazepam nasal spray, by Acorda Therapeutics reads like a licensing deal: $2m upfront; some R&D payments; $18m development and ... 300. Neuronex / Acorda. Collaboration and license.

  • Multiplying options for MS

    Acorda and Biogen Idec's Ampyra (fampridine sustained-release), a potassium channel antagonist that has been shown to restore conduction in demyelinated axons in patients with MS, was approved in the

  • A competitive edge

    Ampyra (Acorda Therapeutics). Multiple sclerosis. USA, Puerto Rico. Desirudin . Iprivask (Canyon Pharmaceuticals).

  • MS symptom drug approved in US

    The drug will be manufactured by Irish pharmaceutical company, Elan, and will be distributed in the US by Acorda Therapeutics. ... Shane Cooke, executive vice president and head of Elan Drug Technologies said: "We wish to congratulate Acorda Therapeutics

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Dr Catherine Strader joins Acorda Therapeutics’ board Dr Catherine Strader joins Acorda Therapeutics’ board

    Dr Catherine Strader joins Acorda Therapeutics’ board. She brings experience from Merck &Co and Synergy Partners R&D Solutions. ... Acorda Therapeutics has expanded its board of directors with the addition of Dr Catherine Strader.

  • Acorda Therapeutics appoints chief medical officer Acorda Therapeutics appoints chief medical officer

    New York-based biotech Acorda Therapeutics has appointed Dr Burkhard Blank as its chief medical officer. ... Burkhard brings to Acorda an impressive record of successful drug development and approved NDAs.

  • Acorda appoints new CFO Acorda appoints new CFO

    Acorda appoints new CFO. Michael Rodgers replaces David Lawrence who becomes chief business officer. ... I'm excited to take on this new challenge at Acorda, overseeing and optimising development of our business operations and infrastructure.”.

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics